Conditional Marketing Authorisation: Early Access to the EU Market, With Obligations Attached

A conditional marketing authorisation lets the EU approve a medicine on less complete data than normal, where patients have an unmet need and the benefit of early access outweighs the risk of evidence still to come. It is a route to market, not a shortcut: the authorisation carries binding obligations, annual renewal and the real possibility of suspension or revocation.

What the route is, and where it comes from

Conditional authorisation is provided for in Regulation (EC) No 726/2004 and elaborated in Regulation (EC) No 507/2006. It applies to products assessed through the centralised procedure by the EMA’s CHMP. It is intended for medicines that treat, prevent or diagnose seriously debilitating or life-threatening diseases, including orphan medicines, and for medicines intended for use in a public health emergency.

The four conditions the CHMP must be satisfied on

All of the following must be met before a conditional authorisation can be granted:

  • the benefit-risk balance of the medicine is positive;
  • the applicant is likely to be able to provide comprehensive data after authorisation;
  • the medicine fulfils an unmet medical need;
  • the benefit of immediate availability outweighs the risk inherent in the fact that additional data are still required.

The unmet-need argument and the plan for post-authorisation evidence are therefore not afterthoughts. They should be built into the development programme and the dossier from the outset, and discussed with the agency early. The EMA advises applicants to notify their intention to seek conditional authorisation around six to seven months before submission.

Obligations, renewal and conversion

A conditional authorisation is valid for one year and is renewed annually. The holder must complete specific obligations within defined timelines, typically finishing ongoing studies, running new ones, or collecting further data to confirm that the benefit-risk balance remains positive. These conditions are published in the European public assessment report (EPAR), so they are visible to regulators, HTA bodies, payers and competitors alike.

Once the obligations are met and the complete data confirm that benefits continue to outweigh risks, the authorisation is converted to a standard one. That standard authorisation is initially valid for five years and can then be renewed for unlimited validity. If new data show the benefit no longer outweighs the risk, or if the holder fails to comply with its obligations, the EMA can act to suspend or revoke the authorisation.

Practical points for MAHs operating in Greece

  • Plan the post-authorisation evidence first. Missed milestones put the licence itself at risk, so confirmatory study feasibility should be tested before submission.
  • Diarise annual renewals. Each renewal needs a prepared package and a clear account of progress against every specific obligation.
  • Align with market access. Payers and HTA assessors will read the same uncertainty the CHMP identified. Evidence generation should serve both the regulatory and the reimbursement questions.
  • Keep pharmacovigilance proportionate to the uncertainty. The risk management plan and any additional monitoring should reflect the data gaps accepted at approval.

The wider EU pharmaceutical reform is also reshaping parts of the regulatory framework, so it is worth checking current requirements rather than relying on older guidance.

How PQRA helps

PQRA supports pharmaceutical companies in deciding whether conditional authorisation is the right route, preparing the justification and the post-authorisation obligation plan, managing renewals and conversion, and aligning regulatory, pharmacovigilance and market access strategy for the Greek and EU markets.

Considering a conditional route for your product? Contact PQRA to discuss your regulatory strategy.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *